Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment

Pietllä, K. O.; Harmoinen, Aimo; Jokiniitty, J.; Pasternack, Amos

doi:10.1093/oxfordjournals.eurheartj.a015068

Cited by 242 publications

(155 citation statements)

References 0 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…11 It has been demonstrated that CRP increases in acute coronary syndromes (unstable angina and AMI) and that it is associated with an adverse outcome regarding both short and long term prognosis. 21,22 It has been reported that increased serum CRP level was associated with a greater increase in LV volume after acute anterior MI. 23 Also CRP is a risk factor for LV thrombus and cardiac rupture after MI.…”

Section: Discussionmentioning

confidence: 99%

Association Between Serum C‐reactive Protein Elevation and Atrial Fibrillation After First Anterior Myocardial Infarction

Gedikli¹,

Örem²,

Baykan³

et al. 2008

Clinical Cardiology

View full text Add to dashboard Cite

Background: Elevated inflammatory markers have been found to correlate with higher risk for cardiac events in patients with acute myocardial infarction (AMI). It has been suggested that C-reactive protein (CRP) may be involved in the initiation process of atrial fibrillation (AF). However, the role of CRP levels in the occurence of AF in patients with AMI has not been studied. This study investigated whether CRP is a risk factor for AF in patients with acute anterior MI. Methods: We prospectively evaluated 92 consecutive patients (25 women and 67 men; aged 58±11 y) with a first acute anterior wall MI. Blood samples were obtained at the time of admission to the hospital, and serum CRP levels were measured by an ultrasensitive immunonephelometry method. All patients were evaluated by echocardiography to measure the left ventricular (LV) diameter and functions. All patients were monitored continuously for the detection of AF in the coronary care unit. Results: Atrial fibrillation occured in 19 (20%) of 92 patients. Univariate analysis showed that patients with AF had an advanced age (63±9.9 versus 56.7±11.7 y, p = 0.034), higher serum CRP level (2.95±2.5 versus 1.71±2.12 mg/dL, p = 0.034), larger LV end-systolic volume (74±15 versus 63±19, mL p = 0.02), higher LV ejection fraction (31.1±6.2 versus 38.4±10%, p = 0.001), and larger left atrial (LA) diameter (37.1±4.2 versus 34.7±3.3 mm, p = 0.01). In multivariate analysis, only age (odds ratio [OR]: 1.05, 95% confidence interval [CI]: 1-1.11, p = 0.036) and CRP levels (OR: 1.27, 95% CI: 1-1.59, p = 0.039) were independent predictors of AF. Conclusion: These results suggest that CRP may be a risk factor for AF in patients with acute anterior wall MI.

show abstract

Section: Discussionmentioning

confidence: 99%

Association Between Serum C‐reactive Protein Elevation and Atrial Fibrillation After First Anterior Myocardial Infarction

Gedikli¹,

Örem²,

Baykan³

et al. 2008

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…24,25 The inflammatory marker hs-CRP has been shown to predict CHD-related morbidity and mortality independent of traditional lipid/lipoprotein risk factors. [24][25][26][27] Previous studies demonstrated that statins reduce hs-CRP levels and ezetimibe 10 mg administered in combination with statins produces further incremental reductions in hs-CRP beyond that achieved with statins alone. 28 Thus, the use of combination lipid-lowering therapies with two different and complementary modes of action may be warranted in high-risk patients with and without diabetes to improve the overall risk profile.…”

Section: Discussionmentioning

confidence: 99%

Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes

Guyton

Betteridge

Farnier³

et al. 2011

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

Treatment guidelines identify low-density lipoprotein cholesterol (LDL-C) as the primary target of therapy with secondary targets of non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (apoB). Data were pooled from 27 randomised, double-blind, active or placebo-controlled trials in 21,794 adult hypercholesterolaemic patients (LDL-C 1.81-6.48 mmol/L) receiving ezetimibe/statin or statin for 4-24 weeks. Percentages of patients achieving various targets were calculated among diabetes (n = 6541) and non-diabetes (n = 15,253) subgroups. Significantly more patients with and without diabetes achieved specified levels of LDL-C (< 2.59, < 1.99, < 1.81 mmol/L), non-HDL-C (< 3.37, < 2.59 mmol/L) and apoB (< 0.9, < 0.8 g/L) with ezetimibe/statin versus statin. Patients with diabetes had larger mean per cent reductions in LDL-C and non-HDL-C than non-diabetes patients. A greater percentage of patients achieved both the LDL-C and apoB targets and all three LDL-C, apoB, and non-HDL-C targets with ezetimibe/statin versus statin in both subgroups. Patients with diabetes benefitted at least as much as, and sometimes more than, non-diabetes patients following treatment with ezetimibe/statin.

show abstract

“…Numerous studies have established the high-sensitivity CRP test with levels ≥3.0 mg/L as the most powerful independent biochemical marker in the prediction of future coronary vascular events and survival in patients with angina pectoris as well as in apparently healthy subjects [71][72][73]. The molecular mechanisms that link CRP to atherogenesis are incompletely understood, but recent investigations have revealed that CRP directly interacts with several major components in the process of atherosclerosis [74,75].…”

Section: :6 Crp In Clinical Practicementioning

confidence: 99%

Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins

Sjöwall

Wetterö

2007

Clinica Chimica Acta

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a systemic rheumatic disease characterized clinically by multiorgan involvement and serologically by the occurrence of antinuclear antibodies. SLE patients may present with multiple autoantibodies to cytoplasmic and cell surface antigens as well as to circulating plasma proteins. Another feature of SLE is that serum levels of C-reactive protein (CRP) often remain low despite high disease activity and despite high levels of other acute phase proteins and interleukin-6, i.e. the main CRP inducing cytokine. Apart from its important role as a laboratory marker of inflammation, CRP attracts increasing interest due to its many intriguing biological functions, one of which is a role as an opsonin contributing to the elimination of apoptotic cell debris, e.g. nucleosomes, thereby preventing immunization against autoantigens. Recently, autoantibodies against CRP and other acute phase proteins have been reported in certain rheumatic conditions, including SLE. Although the presence of anti-CRP autoantibodies does not explain the failed CRP response in SLE, antibodies directed against acute phase proteins have several implications of pathogenetic interest. This paper thus highlights the biological and clinical aspects of native and monomeric CRP and anti-CRP, as well as autoantibodies against mannose-binding lectin, serum amyloid A and serum amyloid P component. © 2006 Elsevier B.V. All rights reserved

show abstract

Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment

Cited by 242 publications

References 0 publications

Association Between Serum C‐reactive Protein Elevation and Atrial Fibrillation After First Anterior Myocardial Infarction

Association Between Serum C‐reactive Protein Elevation and Atrial Fibrillation After First Anterior Myocardial Infarction

Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes

Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins

Contact Info

Product

Resources

About